FDA accelerates approval of Tecentriq joint Abraxane first-line treatment of triple-yin breast cancer

recently, Genentech announced
FDA(http://accelerated approval of Tecentriq's combination abraxane (albumin yew alcohol) first-line treatment of PD-L1-positive partially rectocted prestage or metastatic trinophonic breast cancerThe FDA's approval is based on PFS data from the IMpassion130 study, and Genentech will continue to conduct a validated clinical study to support Tecentriq's full approval for this indicationThe IMpassion130
IMpassion130 study is a multicenter randomized double-blind phase III clinical study that evaluated Atezzumab's combination of albumin ligool to treat pre-stage or metastatic triylnophenic breast cancer without previous systemic treatmentEfficacy, Safety and Pharmacodynamics, in a group of 902 patients, the main focus of the study was THE RECIST 1.1 standard evaluation of PFS and OS, in all intended therapeutic populations and PD-L1-positive populationanalysis(http://The results showed that using Abraxane alone reduced the risk of disease deterioration or death in patients with advanced or metastatic triennoid breast cancer without systematic treatment by 40 percent, with PFS at 7.4 and 4.8 months, respectivelyIn terms of safety
the safety data of the twodrug(http://were consistent with the safety data used alone, and no new adverse reaction signals were found The most common levels of severe adverse reactions of 3-4 (-2%) included decreased white blood cell count, tingling or numbness of the hands and feet, decreased neutrophil count, tiredness, decreased red blood cell count, decreased blood potassium levels, pneumonia, and increased AST 　　Tecentriq's 2018 global sales were CHF 772 million, making triple-breast cancer its third-largest indication after bladder and lung cancer, and the first approved PD-1/PD-L1 immunotherapy drug for breast cancer